Drug intelligence / Profile preview

CKL22

Development stage: Preclinical
Lead developer: Prostemics
Modality: Recombinant Proteins and Enzymes, RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules

Overview

**CKL22** is a preclinical, stem-cell-derived exosome therapeutic being developed by Prostemics in collaboration with CK-Exogene for hepatocellular carcinoma. The exosomes are loaded with the multikinase inhibitor sorafenib, TNF-related apoptosis-inducing ligand, and microRNA-335. The intended antitumor mechanism combines sorafenib-mediated multikinase inhibition, TRAIL receptor-mediated apoptosis induction, and miR-335-associated activation of the p53 tumor-suppressor pathway.

Targets

TP53 (Cellular Tumor Antigen p53 R175H)TNFRSF10B (DR5)TNFRSF10A (Tumor necrosis factor receptor superfamily member 10A)

Beyond the preview

Go deeper on CKL22.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CKL22.

Explore the full profile